T2	eligibility 499 568	women with stage I-III breast cancer who completed adjuvant treatment
T3	intervention-participants 607 609	16
T4	intervention-participants 624 626	11
T5	intervention-participants 644 645	3
T6	control 671 678	placebo
T7	control-participants 684 686	10
T14	total-participants 1020 1022	40
T15	total-participants 1047 1049	34
T16	intervention-participants 1051 1053	26
T17	control-participants 1062 1067	eight
T18	outcome 1224 1245	mean serum HGF levels
T19	outcome 1385 1395	serum VEGF
T20	outcome 1563 1580	serum cholesterol
T1	intervention 13 44	green tea extract, Polyphenon E
T8	outcome-Measure 807 903	growth factor [serum hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF)],
T9	outcome-Measure 904 944	lipid (serum cholesterol, triglycerides)
T10	outcome-Measure 946 962	oxidative damage
T11	outcome-Measure 967 990	inflammatory biomarkers
